The company known as Human Longevity Inc. is an innovative biotechnology company that can be described as operating in the field of health intelligence. The firm is working diligently to improve the quality of life by way of compiling a major database that contains a wealth of data both genomic and of a phenotypic nature. This is combined with innovative machine learning technology that allows for discoveries to be found at a rapid rate. Through its comprehensive database and unique technology based on machine learning, Human Longevity Inc. is helping to generate a new level of insight into the world of health. The dedication to this important work has been instrumental in helping the privately held San Diego, California-based operation to grow extensively since its 2013 launch. The company has also grown to now employ some 150-plus workers.
One would be hard-pressed to not be impressed by the list of areas that are specialized in by Human Longevity Inc. These specialties include imaging of a magnetic resonance nature, executive physicals, metabolome analysis, DNA and RNA sequencing, and assessments of health risk, to name a few. The expert ability that the firm has demonstrated in these areas has been a driving force behind its steady growth over the past five years.
Among the types of things that Human Longevity Inc. points out is the importance of DNA when it comes to determinations of health in individuals. This is a major reason why the firm has been so committed to producing its detailed database. The more data that can be assessed, the greater the possibilities to continue and find new solutions for the improvement of human life as well as its extension. The staff of experts at Human Longevity Inc. is completely committed to making a major difference in today’s world through this critical work. The end goal is a humanity that lives at a higher quality of overall life.
Human Longevity Inc. is the creation of entrepreneurs Peter Diamandis and Craig Venter. It is the vision of these two forward-thinking and innovative businessmen that have been pushing the work forward with the firm and helping to make a tangible change in the world’s health. After the 2013 founding, the two co-founders were able to bring in a tremendous amount of investment capital by way of both a Series A and Series B funding round. The former brought in $80 million while the latter, which took place in 2016, garnered some $220 million. Human Longevity Inc. has also struck some impressive deals with leading pharmaceutical industry firms such as AstraZeneca and the Celgene firm.
The executive team at Human Longevity Inc. is truly impressive. This outstanding team includes President David Karow, Chief Corporate Development Officer Travis Lacey, and CTO Scott Sorensen. They are joined by seasoned professionals such as Chief Commercial Officer Noah Nasser as well as Michael Doney who serves in the capacity of Medical Director. With a team of experts in the industry of this level of prestige, it is no shock that Human Longevity Inc. has been able to so quickly grow and begin to make a major difference in the state of health.
